Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05101902 · ClinicalTrials.gov registry record
A Study to Determine Eligibility for CAH-301 (A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) [NCT04783181])
A clinical trial, sponsored by Adrenas Therapeutics.
- Completed
- Registry status
- 65
- Enrollment target
NCT05101902: Completed study, sponsored by Adrenas Therapeutics.
NCT05101902 is a clinical trial that has completed, run by Adrenas Therapeutics. The registered enrollment target is 65 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05101902 has completed, sponsored by Adrenas Therapeutics.
- COMPLETED
- Registry status
- 65 participants
- Enrollment target
Study Summary
This pre-screening study is designed to determine potential eligibility of adults with classic CAH due to 21-hydroxylase deficiency (21-OHD) for participation in the CAH-301 \[NCT04783181\] gene therapy trial with BBP-631.
Interventions
- OTHER Pre-Screening
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2024-08-07 |
What the finished NCT05101902 record still lists
NCT05101902 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 65 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Pre-Screening is the first listed.
NCT05101902 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05101902 about?
NCT05101902 is a clinical study titled "A Study to Determine Eligibility for CAH-301 (A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) [NCT04783181])". This pre-screening study is designed to determine potential eligibility of adults with classic CAH due to 21-hydroxylase deficiency (21-OHD) for participation in the CAH-301 \[NCT04783181\] gene therapy trial with BBP-631.
What is the current status of trial NCT05101902?
This trial is currently completed. The enrollment target is 65 participants. The study started on 2021-07-01. Estimated completion is 2024-08-07.
What interventions are being tested in trial NCT05101902?
The interventions under investigation include: Pre-Screening (OTHER).
Who is sponsoring clinical trial NCT05101902?
This trial is sponsored by Adrenas Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI